Aldeyra Therapeutics (ALDX) Stock Price, News & Analysis

Company Overview

Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases. The company’s research centers on reactive aldehyde species, or RASP, which are inflammatory signaling molecules that may contribute to ocular and systemic diseases.

Aldeyra’s lead investigational product is reproxalap, an eye drop designed to inhibit RASP activity. The company has studied reproxalap in conditions including dry eye disease and allergic conjunctivitis. Aldeyra has also evaluated additional RASP-targeting compounds and has pursued ophthalmic treatments for other diseases involving inflammation and immune dysregulation.

Founded in 2008 and headquartered in Lexington, Massachusetts, Aldeyra conducts clinical development activities intended to support potential commercialization in the United States and international markets. The company is led by Todd C. Brady, M.D., Ph.D., who serves as president and chief executive officer. As a development-stage biotechnology company, Aldeyra’s products remain subject to clinical, regulatory, and commercial uncertainties.

Key Stats

• Today's Range: $0.60 to $0.66
• 50-Day Range: $0.56 to $1.54
• 52-Week Range: $0.53 to $5.93
• Volume: 569,299 shs
• Average Volume: 900,617 shs
• Market Capitalization: $38.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

Aldeyra Therapeutics Stock Analysis - MarketRank™

Aldeyra Therapeutics scored higher than 62% of companies evaluated by MarketBeat, and ranked 374th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Aldeyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Aldeyra Therapeutics has a consensus price target of $2.00, representing about 217.4% upside from its current price of $0.63.

Amount of Analyst Coverage

Aldeyra Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aldeyra Therapeutics are expected to grow in the coming year, from ($0.27) to ($0.10) per share.

Price to Book Value per Share Ratio

Aldeyra Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.94% of the float of Aldeyra Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aldeyra Therapeutics has a short interest ratio ("days to cover") of 3.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aldeyra Therapeutics has recently decreased by 0.84%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aldeyra Therapeutics does not currently pay a dividend.

Dividend Growth

Aldeyra Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.68

News Sentiment

Aldeyra Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Aldeyra Therapeutics this week, compared to 6 articles on an average week.

MarketBeat Follows

1 people have added Aldeyra Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aldeyra Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.80% of the stock of Aldeyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

59.71% of the stock of Aldeyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/05/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ALDX
• CIK: 1341235
• Web: www.aldeyra.com
• Phone: 781-761-4904
• Fax: 781-270-0630
• Employees: 6
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Aldeyra Therapeutics: $2.00
• High Price Target: $2.00
• Low Price Target: $2.00
• Potential Upside/Downside: +217.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.97%
• Return on Assets: -33.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.45
• Quick Ratio: 5.45

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.58 per share
• Price / Book: 1.09

Miscellaneous

• Outstanding Shares: 60,360,000
• Free Float: 53,235,000
• Market Cap: $38.03 million
• Optionable: Optionable
• Beta: 1.32